Literature DB >> 17891187

Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation.

A Bjorklund1, J Aschan, M Labopin, M Remberger, O Ringden, J Winiarski, P Ljungman.   

Abstract

Infectious complications remain a major problem contributing to significant mortality after hematopoietic allogeneic stem cell transplantation (HSCT). Few studies have previously analyzed mortality due to late infections. Forty-four patients dying from an infectious complication were identified from a cohort of 688 consecutive patients surviving more than 6 months without relapse. A control group of 162 patients was selected using the year of HSCT as the matching criterion. Out of 44 patients, 30 (68%) died from pneumonia, 7/44 (16%) from sepsis, 5/44 (11%) from central nervous system infection and 2/44 (4.5%) from disseminated varicella. The cumulative incidences of different types of infection were 1.6% for viral, 1.5% for bacterial and 1.3% for fungal infections and 0.15% for Pneumocystis jirovecii pneumonia. The majority (66%) of the lethal infections occurred within 18 months after HSCT. Acute GVHD (relative risk (RR): 7.19, P<0.0001), chronic GVHD (RR: 6.49, P<0.001), CMV infection (RR: 4.69, P=0.001), mismatched or unrelated donor (RR: 3.86, P=0.004) and TBI (RR: 2.65, P=0.047) were independent risk factors of dying from a late infection. In conclusion, infections occurring later than 6 months after HSCT are important contributors to late non-relapse mortality after HSCT. CMV infection or acute GVHD markedly increase the risk.

Entities:  

Mesh:

Year:  2007        PMID: 17891187     DOI: 10.1038/sj.bmt.1705856

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  25 in total

Review 1.  [Infections of the central nervous system in the immuno-compromised].

Authors:  E Schmutzhard; B Pfausler
Journal:  Nervenarzt       Date:  2008-09       Impact factor: 1.214

2.  Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies.

Authors:  Takayoshi Tachibana; Masatsugu Tanaka; Hirotaka Takasaki; Ayumi Numata; Satomi Ito; Reina Watanabe; Rie Hyo; Rika Ohshima; Maki Hagihara; Rika Sakai; Shin Fujisawa; Naoto Tomita; Hiroyuki Fujita; Atsuo Maruta; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Int J Hematol       Date:  2011-02-18       Impact factor: 2.490

Review 3.  Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care.

Authors:  Minoo Battiwalla; André Tichelli; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-03       Impact factor: 5.742

Review 4.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

5.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

6.  Clinical utility of computed tomography screening of chest, abdomen, and sinuses before hematopoietic stem cell transplantation: the St. Jude experience.

Authors:  Kimberly A Kasow; Jennifer Krueger; Deo Kumar Srivastava; Chenghong Li; Raymond Barfield; Wing Leung; Edwin M Horwitz; Renee Madden; Paul Woodard; Ishtiaq Hussain; M Beth McCarville; Rupert Handgretinger; Gregory A Hale
Journal:  Biol Blood Marrow Transplant       Date:  2009-02-12       Impact factor: 5.742

7.  Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years.

Authors:  Ji-min Shi; Xu-ying Pei; Yi Luo; Ya-min Tan; Ru-xiu Tie; Jing-song He; Wei-yan Zheng; Jie Zhang; Zhen Cai; Mao-fang Lin; He Huang
Journal:  J Zhejiang Univ Sci B       Date:  2015-09       Impact factor: 3.066

8.  Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation.

Authors:  Ashok Srinivasan; Chong Wang; Deo K Srivastava; Ken Burnette; Jerry L Shenep; Wing Leung; Randall T Hayden
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-23       Impact factor: 5.742

9.  Late infectious complications in hematopoietic cell transplantation survivors: a population-based study.

Authors:  Aimee M Foord; Kara L Cushing-Haugen; Michael J Boeckh; Paul A Carpenter; Mary E D Flowers; Stephanie J Lee; Wendy M Leisenring; Beth A Mueller; Joshua A Hill; Eric J Chow
Journal:  Blood Adv       Date:  2020-04-14

10.  Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD).

Authors:  Baerbel Spies-Weisshart; Kristina Schilling; Frank Böhmer; Andreas Hochhaus; Herbert G Sayer; Sebastian Scholl
Journal:  J Cancer Res Clin Oncol       Date:  2013-06-01       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.